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Calcium Channel Blockers in the Management of Myocardial
Infarction Patients*

Mihai Gheorghiade, MD^

I

ncreased cardiovascular mortality during the post myocardial
infarction (MI) period is related to left ventricular dysfunction, recurrent infarction, and arrhythmias. Several trials have
demonstrated conclusively the effectiveness and safety of betablocker therapy for patients recovering from acute MI (1,2). Although structurally heterogeneous, calcium channel blockers
are a group of drugs that have in common the pharmacological
property of blocking or reducing the entrance of calcium into
cardiac and smooth vascular muscle (3). The following agents
are approved for use in the United States: diltiazem, verapamil,
nifedipine, nicardipine, bepridil, isradipine, and nimodipine.
For several years these agents have been used successfully in
the treatment of vasospastic angina, exertional angina, unstable
angina, supraventricular arrhythmias (verapamil, diltiazem),
hypertension, and symptomatic hypertrophic cardiomyopathy
(verapamil). Several experimental studies examined the effects
of calcium channel blockers in experimental MI. In general,
they have shown favorable results affecting infarct size in animal models (4-13). Because, unlike beta-blockers, the structure
and cardiovascular pharmacology of calcium channel blockers
are heterogeneous (14), this report will evaluate separately the
effects of different calcium channel blockers in patients with
suspected or confirmed MI.

Calcium Channel Blockers in
Undifferentiated Acute M I
Nifedipine
The Nifedipine Angina Myocardial Infarction Study (NAMIS)
(15) randomized patients with suspected MI within 6 hours after onset of symptoms to nifedipine or placebo; the therapy
was continued for 14 days. The progression to Ml was identical
(75%) in the placebo and nifedipine groups. Although the twoweek mortality rate was higher in the nifedipine group when
compared with the placebo group at six months of follow-up,
the mortatity rate was approximately 10% in both groups (Table 1).
The Norwegian Nifedipine Multicenter Trial (16) examined
patients with suspected MI enrolled within 12 hours of the onset
of symptoms and randomized to nifedipine or placebo for a period of six weeks. There was a trend toward a larger infarct size
in the nifedipine group. This was particularly evident in patients
with hypotension or an increased heart rate at thetimeof the ran-
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domization. At six months of follow-up, no differences in mortality were observed between the nifedipine and placebo groups
(Fig I).
The Trial of Early Nifedipine in Acute Myocardial Infarction
(TRENT) (17) studied a large number of patients with suspected
MI within 24 hours after the onset of symptoms. Those patients
were randomized between two groups to receive initially two
doses of sublingual nifedipine followed by oral nifedipine or
placebo that was continued for the next 30 days. At one month
of follow-up, the mortality rate in patients with confirmed MI
was 10.2% in the nifedipine group and 9.3% in the placebo
group. These differences were not statistically significant. Compared with the placebo group, the nifedipine-treated group was
found to have a significant decrease in both systolic and diastolic blood pressure and an increase in heart rate. Ventricular
arrhythmias, including ventricular fibrillation, were similar in
the two groups. No benefit in the nifedipine-treated patients was
observed in those randomized within 4 hours, as well as within
4 to 24 hours, after onset of symptoms. Since the cardiac events
were similar in the two groups, this study was terminated prematurely.
The Secondary Prevention Reinfarction Israeli Nifedipine
Trial (SPRINT-I) (18) randomized a large number of patients
with confirmed MI 7 to 21 days after the event to nifedipine or
placebo; therapy continued for one year. No significant differences in infarct size were detected between the two groups. The
reinfarcfion rate was low and not different between the nifedipine or placebo groups. Similarly, the mortality rate was identical in the two groups. No differences were found between placebo and nifedipine-treated patients when patients were stratified in three groups (male-first MI, male-second MI, and female).
The SPRINT-II (19) enrolled high-risk acute MI patients
(prior MI, anterior location, angina) lo nifedipine or placebo.
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Fig 1—Life-table of survival for all patients randomly assigned
to treatment. (From Sirnes PA. Overskeid K, Pedersen TR, et al.
Evolution of infarct size during the early use of nifedipine In patients with acute myocardial infarction: the Norwegian Nifedipine Multicenter Trial. Circulation 1984;70:638-44. Reprinted
with permission.)
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The study was terminated early due to an excess mortality noted
in the nifedipine group. This excessive mortality rate was particularly apparent during the first six days of the study.
Muller et al (20) studied patients with unstable angina who
were randomized to nifedipine or placebo for 14 days. In a subset of patients not receiving prior propranolol, initiation of conventional therapy produced more rapid pain relief than initiation
of nifedipine therapy, which tended to increase the heart rate.
For the study population as a whole, nifedipine alone was equivalent to conventional therapy for unstable angina (Fig 2). This
study suggests that combination nifedipine and beta-blocker
therapy is safe and beneficial in patients with unstable angina.
The Holland Intemniversity Nifedipine/Metoprolol Trial (21)
studied the effects of nifedipine, metoprolol, and their combination in patients with unstable angina. The endpoints were recurrent ischemia and infarction at 48 hours of follow-up. This study
was terminated early because the interim analysis showed that
the risk of developing acute MI was higher in the group receiving nifedipine alone. In the group that received prior betablocker therapy, the addition of nifedipine was beneficial in reducing ischemia. In patients not receiving a beta-blocker, nifedipine caused an increase in Ml and ischemia. The combination

Fig 2—The probability of being pain-free for at least 48 hours
in the group ofall eligible patients randomly assigned to a therapy (n = 126). There was no significant difference in pain relief
between those treated with conventional therapy (dashed line)
and those treated with nifedipine (solid line). (From Muller JE,
Turt ZG, Pearle DL, et al. Nifedipine and conventional therapy
for unstable angina pectoris: A randomized, double-blind comparison. Circulation 1984;69:728-39. Reprinted with permission.)

of metoprolol and nifedipine had no advantage over metoprolol
alone.
Walker et al (22) examined patients with suspected MI enrolled within the first 6 hours after onset of symptoms. Patients
were randomized to nifedipine sublingually, then orally for the
next 24 hours, or placebo. At two weeks of follow-up, the mortality and reinfarction rates were similar in the two groups. The
incidence of ventricular arrhythmias in-hospital was similar.

Table 1
Long-term Randomized Clinical Trials of Nifedipine in Patients with Suspected or Confirmed Myocardial Infarction

Study
NAMIS (1984) (15)
Norwegian Trial (1984) (16)
TRENT (1986) (17)
SPRINT (1988) (18)
Gonliebet al(1988)(23)
Walker et al (1988) (22)
SPRINT n (1988) (19)
Erbel etal (1988) (25)

Number of
Patients
171
227
4.491
2.276
132
434
1.373
149

Entry After
Symptoms
< 6 hrs
< 12 hrs
< 24 hrs
7-21 days
< 12 hrs
<6hrs
< 48 hrs
6 hrs

Oral Daily
Dose

Duration of
Therapy

120 mg
40 mg
40 mg
30 mg
120 mg
60 mg
60 mg

14 days
6 weeks
30 days
12 months
6 weeks
14 days
6 months

60 mg

28 days

Reinfarction
I
F

Mortality
I

P

7
2,2%
4,4%
9,3%
4,7%

7
?
1.5%
4.8%
10,2%
2,5%
7

10,1%
8,9%
10,2%
5,8%
6,2%
6,6%
15,4%

8,5%
8,7%
9,3%
5,7%
5,8%
5,8%
13,2%

16.0%

11,0%

13,0%

8,0%

Statistical
Significance
None
None
None
None
None
None
Excess
mortality
None

I = intervention with nifedipine. P = placebo.
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Erbel et al (25) examined patients with suspected MI who received intravenous and intracoronary streptokinase within the
first 6 hours after onset of symptoms. These patients were randomized into two groups: nifedipine, 20 mg sublingually and
intracoronary, followed by nifedipine, 20 mg orally three times
a day for the duration of the hospital stay, or placebo. In both
groups the mean time between onset of symptoms and the beginning of treatment was 2.5 hours. Creatine kinase (CK) MB
isoenzyme release was higher in the nifedipine group. All patients underwent cardiac catheterization. Patients who continued to have an occlusion in the infarct-related artery underwent
coronary angioplasty. In-hospital mortality was 13% in the
nifedipine group and 8% in the placebo group. The incidence of
reinfarction was 16% in the nifedipine group compared with
11% in the placebo group. The reocclusion rate was 20% in the
nifedipine group compared with 13% in the placebo group. Ventricular function was similar in the two groups. The incidence of
ventricular arrhythmias seemed to be reduced by the administration of nifedipine.
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Fig 3—Cumulative death rate for all patients included In study.
(From The Danish Study Group on Verapamil in Myocardial Infarction. Eur Heart J 1984;5:516-28. Reprinted with permission.)

Gottiieb et al (23) randomized low-risk acute MI patients enrolled within the first 12 hours after onset of symptoms to nifedipine or placebo. At six weeks of follow-up, no significant differences between the two groups were noted in left ventricular
funcfion and dimensions and infarct size. The mortality and reinfarction rates were similar in the two groups.
Branagan et al (24) studied patients with suspected MI, randomized to nifedipine sublingually and followed by oral nifedipine for two days, or placebo. There were no differences between the two groups with regard to a one-month mortality rate
or the progression to acute Ml.

It appears from the above studies that nifedipine does not reduce infarct size, reinfarction, or mortality in patients with suspected or confirmed MI when given eariy (less than 24 hours) or
in the posfinfarction period. This lack of benefit is noted in all
patients: male or female, those at low risk or high risk, those
with ST elevation or ST depression, or when used alone or in
combination with a beta-blocker or a thrombolytic agent. Some
ofthe studies suggest that nifedipine may have a detrimental effect, particularly in patients with a relatively decreased blood
pressure and/or increased heart rate. This detrimental effect may
be related to a sudden and marked decrease in blood pressure resulting in a decrease in coronary artery perfusion pressure (26),
disproportional dilatation in the coronary artery adjacent to the
ischemic area (coronary artery steal), or reflex activation of the
sympathetic nervous system (27) with a resultant increase in
myocardial contractility and heart rate and, thus, myocardial oxygen consumption.
Verapamil
The Danish Verapamil Infarction Trial (DAVIT-I) (28) randomized 3,498 patients with confirmed MI into two groups: intravenous verapamil or placebo (Table 2). Of these, 1,436 had a
confirmed Ml and therapy with oral verapamil or placebo was
continued. Enrollment occurred in the first 48 hours after onset
of symptoms (58% of patients were enrolled within 6 hours,
26% between 6 and 24 hours, and 16% between 24 and 48

Table 2
Long-term Randomized Clinical Trials of Verapamil in Patients with Suspected or Confirmed Myocardial Infarction
Number of
Patients

Study
DAVIT-I (1984) (28)
DAVIT-II(I990)(30)

1,436
1,775

Entry After
Symptoms
< 48 hrs
7-15 days

Oral Daily
Dose

Duration of
Therapy

360 mg
360 mg

6 months
16 months

Reinfarction
I
P
7,0%.
11,0%

I

8,3%:
13,2%

Mortality
P

12,8%
11,1%

13,9%
13,8%

Statistical
Significance
None

(mortality and reinfarction).
I = intervention with verapamil, P - placebo.
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hours). Patients over 75 years of age and those with cardiogenic
shock, heart failure, sinoatrial or atrioventricular block, or concomitant therapy with a calcium channel blocker or beta-blocker
were excluded. At six months of follow-up, the mortality and reinfarction rates were similar in the verapamil and the placebo
groups (Fig 3). However, the in-hospital complication rate was
significantly greater in patients who received verapamil therapy
(heart failure, second- or third-degree atrioventricular block),
resulting in early withdrawal. There was also an excess in-hospital mortality rate from cardiogenic shock in the verapamil
group. However, verapamil-treated patients who survived for 14
days and 21 days had a lower mortality and reinfarction rate,
respectively, at six months of follow-up. In 100 patients in the
DAVIT-1 (29), randomized within 4 hours after the onset of
symploms of acute MI to verapamil or placebo, infarct size was
similar in the verapamil and placebo groups.

16
.r

12

3

8 -

4 -

The DAVIT-II (30) examined 1,775 patients with confirmed
MI; 878 were randomized to verapamil and 897 to placebo approximately 10 days after the index MI. After 18 months there
was no significant reduction in mortality in the verapamil group
compared to the placebo group. Cardiac events defined as mortality and reinfarction combined were lower in the verapamil
group. Subgroup analyses demonstrated that heart failure was
related to the event rate. In the group of pafients without heart
failure, verapamil therapy caused a significant reduction in 18month mortality and/or reinfarction. The group with no heart
failure constituted 65% of the total study population. No significant differences were found between the two treatment groups
in the remaining 35% of patients with heart failure (Fig 4).
It appears that verapamil may be useful in reducing mortality
and reinfarction rate when used in patients with preserved left
ventricular function and no signs of heart failure and when
started several days after the acute MI. Verapamil is relatively
contraindicated in patients with heart failure or bradyarrhythmias or in the first 24 to 48 hours after the onset of symptoms of
the acute Ml.
Diltiazem
The Multicenter Diltiazem Postinfarction Trial (MDPIT) (31)
evaluated the effect of diltiazem on cardiac event rate (mortality
and/or reinfarction) in a large number of patients who had a recent MI (Table 3). The mean follow-up was 25 months. Although the incidence of cardiac events, mortality rate, and reinfarction was lower in the diltiazem group, this difference was
not statistically significant. Patients receiving diltiazem had an

Placebo N o Heart Failure
Placebo Heart Failure
V e r a p a m i l N o Heart Failure
V e r a p a m i l Heart F a i l u r e '
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Fig 4—Cumulative mortality rates in patients with and without
heartfailure (P = 0.02), according to treatment. The numbers of
patients at risk are shown at the bottom (placebo, no heart failure, n = 574; verapamil, no heart failure, n = 587; placebo,
heartfailure, n = 323; verapamil, heart failure, n = 291). (From
the Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events afler
acute myocardial infarction. Am J Cardiol 1990;66:779-85. Reprinted wtth permission).

increased incidence of atrioventricular block and hypotension.
Patients without pulmonary congestion on chest x-ray or a left
ventricular ejection fraction of greater than 40%, representing
80% of the patients enrolled, had a 30% reduction in cardiac
events when compared with the placebo group. In contrast, in
patients with pulmonary congestion on chest x-ray, diltiazem
was associated with a significant 25% increase in cardiac events
(Fig 5).

Table 3
Long-term Randomized Clinical Trials of Diltiazem in Patients with Suspected or Confirmed Myocardial Infarcfion
Study
DRS (1986) (36)
MDPIT(1988) (31)

Numberof
Patients
576*
2.466

Entry After
Symptoms
24-72 hrs
3-5 days

Oral Daily
Dose

Duration
of Therapy

360 mg
240 mg

2 weeks
25 months

Reinfarction
I
P
5.2%
8.0%

9,3%
9,4%

Mortality
1
3,8%
10,3%

P
3,1%
10,0%

Statistical
Significance
Less reinfarction

t

•Confirmed non-Q wave myocardial infarction,
tSubgroup analysis suggests that in patients wilhout heart failure in the coronary care unil, dikiazem when compared to placebo caused a significant reduction in major cardiac events
(mortality and reinfarction),
I = intervention with a calcium channel blocker, P = placebo.
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Fig 5—Cumulative rate of first recurrent cardiac events, according to treatment in patients with and without pulmonary
congestion. Diltiazem-treated patients with pulmonary congestion had a higher rate of cardiac events than patients receiving
placebo; diltiazem-treated patients without pulmonary congestion had a lower rate of cardiac events than patients receiving
placebo. (From the Multicenter Diltiazem Postinfarction Trial
Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;3I9:
385-93. Reprinted with permission.)

Non-Q Wave MI
Non-Q wave MI patients are different compared to Q wave
Ml patients (32). They have a smaller infarct size, more frequent
patent infarct-related artery, and a larger residual mass of viable
myocardium at risk wilhin the pertusion zone of the infarctrelated artery (33). Although the initial mortality is lower, the
long-term prognosis is the same or even worse when residual
ischemia is present, when compared to patients with Q wave Ml
(34). The pathophysiologic mechanism is probably related to
transient coronary occlusion with spontaneous reperfusion (35).
The only study to be conducted prospectively in patients with
non-Q wave MI was the multicenter Diltiazem Reinfarction
Study (DRS) (36). In this trial, 576 patients were randomized
into two groups: diltiazem, 90 mg four times a day, or placebo
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Fig 6—Life-table cumulative reinfarction rates, according to
treatment gi-oup. (From Gibson RS. Boden WE. Theroux P. et al.
Diltiazem and reinfarction in patients with non-Q wave myocardial infarction; Results of a double-blind, randomized, multicenter trial. N Engl J Med 1986 ;315:423-9. Reprinted with
permission.)

for 14 days. The treatment began 24 to 72 hours after onset
of symptoms. In both placebo and diltiazem groups, approximately 60% of patients received beta-blocker therapy and 80%
were taking nitrates. The combination of diltiazem and (3-adrenergic blockers was well tolerated. During the 14-day followup, the reinfarction rate (Fig 6) and postinfarction angina were
significantiy lower in the diltiazem group when compared with
placebo. The 14-day mortality rate was low and not different in
the two groups. However, this study showed that despite maximal medical therapy with calcium channel blockers, beta-blockers, and nitrates, patients with non-Q wave MI developing postinfarction angina associated with electrocardiographic changes
have a higher mortality (37) in the immediate postinfarction period. In addition, persistent ST depression (38,39) was an indicator of increased mortality and reinfarction at one year of follow-up.
In the MDPIT, Boden et al (40) found that patients with the
first non-Q or the first inferior Q wave infarction who have a
preserved left ventricular function appear to benefit from chronic dilfiazem therapy (Fig 7). In this subgroup analysis, it was
found that patients with their first non-Q wave Ml, despite pulmonary congestion on chest x-ray at the time of admission, also
had a lower mortality compared to the placebo group. This study
concluded that long-term therapy with diltiazem may decrease
the instance of recurring cardiac events in most patients after a
non-Q or an inferior Q wave MI. However, such treatment is not
indicated for patients with multiple infarctions or for those who
exhibit pulmonary congestion or other objective evidence of left
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Fig 7—Kaplan-Meier life-table analysis of time to first recurrent (REC) cardiac eventfor the patients with acute non-Q wave
acute myocardial infarction (MI). MDPIT = Multicenter Diltiazem Postinfarction Trial; solid line = diltiazem; dashed line
= placebo. (From Boden WE. Krone RJ. Klelger RE. et al. Electrocai-dlographic subset analysis of diltiazem administration on
long-term outcome after acute myocai-dlal infarction. Am J Cardiol 1991 ;67;335-42. Reprinted with permission.)

ventricular dysfunction after the Q wave infarction, regardless
of electrocardiographic location.
Recentiy Moss et al (41) found that diltiazem is of benefit in
patients recovering from a Q and non-Q wave MI who have a
history of hypertension and preserved left ventricular function.
In contrast, patients with hypertension and a decrease in left
ventricular ejecfion fracfion had an increase in cardiac events in
response to diltiazem therapy.
From these studies, it appears that patients who benefit most
from long-term diltiazem are those with a non-Q wave MI or patients with a Q wave Ml with preserved left ventricular function
and no signs of heart failure, particulariy if they have a history of
hypertension.
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Fig 8—Life-table analysis showing occurrence of new or worsened congestive heart failure (CHF) in postinfarction patients
with ejection fraction (EF) of < 0.40 at study enrollment. Percent remaining without CHF (vertical axis) is plotted against
days after study enrollment (horizontal axis). Initially, 326 patients were assigned to placebo (dashed line) and 297 were assigned to diltiazem (solid line). Numbers of patients participating in follow-up on days 300,600,900. and 1.200 are shown (as
placebo/diltiazem) above horizontal axis. (From Goldstein RE.
Boccuzzi SJ. Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991 ;83;52-60. Reprinted
with permission.)

tients with small MI (Q and non-Q wave MI) and no history of
heart failure. In contrast, beta-blockers are particularly beneficial in patients with large Mls and/or a history of heart failure
(50).

Therapeutic Implications
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